title: Development of a preclinical PK/PD model to assess antitumor response of a sequential aflibercept and doxorubicin-dosing strategy in acute myeloid leukemia.
abstract: Timing of the anti-angiogenic agent with respect to the chemotherapeutic agent may be crucial in determining the success of combination therapy in cancer. We investigated the effects of sequential therapy with the potent VEGF inhibitor, aflibercept, and doxorubicin (DOX) in preclinical acute myeloid leukemia (AML) models. Mice were engrafted with human HL-60 and HEL-luciferase leukemia cells via S.C. and/or I.V. injection and treated with two to three doses of aflibercept (5-25 mg/kg) up to 3-7 days prior to doxorubicin (30 mg/kg) administration. Leukemia growth was determined by local tumor measurements (days 0-16) and systemic bioluminescent imaging (days 0-28) in animals receiving DOX (3 mg/kg) with or without aflibercept. A PK/PD model was developed to characterize how prior administration of aflibercept altered intratumoral DOX uptake. DOX concentration-time profiles were described using a four-compartment PK model with linear elimination. We determined that intratumoral DOX concentrations were 6-fold higher in the aflibercept plus DOX treatment group versus DOX alone in association with increased drug uptake rates (from 0.125 to 0.471 ml/h/kg) into tumor without affecting drug efflux. PD modeling demonstrated that the observed growth retardation was mainly due to the combination of DOX plus TRAP group; 0.00794 vs. 0.0043 h(-1). This PK/PD modeling approach in leukemia enabled us to predict the effects of dosing frequency and sequence for the combination of anti-VEGF and cytotoxic agents on AML growth in both xenograft and marrow, and may be useful in the design of future rational combinatorial dosing regimens in hematological malignancies.
authors.affiliation: PK/PD Core Facility, Department of Medicine, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263, USA. gerald.fetterly@roswellpark.org
authors.forename: Gerald J
authors.initials: GJ
authors.lastname: Fetterly
authors.forename: Urvi
authors.initials: U
authors.lastname: Aras
authors.forename: Deepika
authors.initials: D
authors.lastname: Lal
authors.forename: Michael
authors.initials: M
authors.lastname: Murphy
authors.forename: Patricia D
authors.initials: PD
authors.lastname: Meholick
authors.forename: Eunice S
authors.initials: ES
authors.lastname: Wang
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000493:pharmacokinetics* / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D004317:Doxorubicin / Q000493:pharmacokinetics* / Q000494:pharmacology; D004353:Drug Evaluation, Preclinical / Q000379:methods; D005260:Female; D018922:HL-60 Cells; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy / Q000378:metabolism*; D051379:Mice; D016513:Mice, SCID; D040262:Receptors, Vascular Endothelial Growth Factor / Q000493:pharmacokinetics* / Q000494:pharmacology; D011993:Recombinant Fusion Proteins / Q000493:pharmacokinetics* / Q000494:pharmacology; D016896:Treatment Outcome; D023041:Xenograft Model Antitumor Assays / Q000379:methods*
chemical_list: D000970:Antineoplastic Agents; D011993:Recombinant Fusion Proteins; C533178:aflibercept; D004317:Doxorubicin; D040262:Receptors, Vascular Endothelial Growth Factor
references.citation: Eur J Cancer. 2010 Nov;46(16):3022-36
references.pmid: 20729074
references.citation: J Clin Oncol. 2011 Mar 10;29(8):979-85
references.pmid: 21282541
references.citation: Cancer Res. 2011 Apr 1;71(7):2675-85
references.pmid: 21447737
references.citation: Br J Clin Pharmacol. 2011 Sep;72(3):402-14
references.pmid: 21575034
references.citation: J Chromatogr B Analyt Technol Biomed Life Sci. 2009 Mar 15;877(8-9):837-41
references.pmid: 19246257
references.citation: Cancer Res. 2005 Feb 1;65(3):671-80
references.pmid: 15705858
references.citation: J Clin Oncol. 2011 Jul 1;29(19):2689-95
references.pmid: 21606416
references.citation: Proc Natl Acad Sci U S A. 2002 Aug 20;99(17):11393-8
references.pmid: 12177445
references.citation: Urology. 2010 Oct;76(4):923-6
references.pmid: 20646741
references.citation: Blood. 2000 Sep 15;96(6):2240-5
references.pmid: 10979972
references.citation: Mol Cancer Ther. 2008 Dec;7(12):3670-84
references.pmid: 19074844
references.citation: Clin Cancer Res. 2004 Jun 1;10(11):3577-85
references.pmid: 15173063
references.citation: Clin Cancer Res. 2007 Nov 1;13(21):6450-8
references.pmid: 17975157
references.citation: Cancer Chemother Pharmacol. 2002 Dec;50(6):490-6
references.pmid: 12451476
references.citation: Cancer Res. 1985 Sep;45(9):4020-5
references.pmid: 4027999
references.citation: N Engl J Med. 2009 Sep 24;361(13):1235-48
references.pmid: 19776405
references.citation: Clin Cancer Res. 2011 Oct 15;17(20):6574-81
references.pmid: 21880788
references.citation: Leukemia. 2006 Jun;20(6):952-7
references.pmid: 16617323
references.citation: Leuk Lymphoma. 2007 Apr;48(4):659-68
references.pmid: 17454623
references.citation: Blood. 2005 Feb 1;105(3):986-93
references.pmid: 15459012
references.citation: Cancer Res. 2011 Feb 1;71(3):686-92
references.pmid: 21123454
references.citation: Clin Cancer Res. 2008 Apr 15;14(8):2405-12
references.pmid: 18413831
references.citation: Leuk Res. 2010 Feb;34(2):196-202
references.pmid: 19674789
references.citation: Pharm Res. 1993 Jul;10(7):1093-5
references.pmid: 8378254
references.citation: Lancet Oncol. 2011 Nov;12(12):1109-17
references.pmid: 21992853
references.citation: Mol Cancer Ther. 2012 Mar;11(3):752-62
references.pmid: 22222630
references.citation: Science. 2005 Jan 7;307(5706):58-62
references.pmid: 15637262
references.citation: AAPS J. 2010 Mar;12(1):1-10
references.pmid: 19902363
references.citation: Leukemia. 2009 Dec;23(12):2233-41
references.pmid: 19727127
references.citation: Blood. 2003 Oct 15;102(8):2763-7
references.pmid: 12843001
references.citation: Cancer Res. 2004 Feb 1;64(3):1094-101
references.pmid: 14871843
references.citation: Leuk Res. 2006 Jul;30(7):801-11
references.pmid: 16332390
references.citation: Cancer Chemother Pharmacol. 1997;39(6):541-6
references.pmid: 9118467
references.citation: Br J Cancer. 1996 Feb;73(4):522-4
references.pmid: 8595168
references.citation: Cancer Res. 2004 Jun 1;64(11):3731-6
references.pmid: 15172975
references.citation: AAPS PharmSci. 2002;4(4):E42
references.pmid: 12646013
references.citation: Leuk Res. 1993 Aug;17(8):663-8
references.pmid: 8355510
references.citation: Eur J Cancer. 1990;26(6):729-32
references.pmid: 2144163
references.citation: Cancer Cell. 2012 Jan 17;21(1):82-91
references.pmid: 22264790
references.citation: Curr Cancer Drug Targets. 2011 Nov;11(9):1053-68
references.pmid: 21999626
references.citation: N Engl J Med. 2009 Sep 24;361(13):1249-59
references.pmid: 19776406
references.citation: Ther Drug Monit. 1993 Oct;15(5):455-61
references.pmid: 8249054
references.citation: Toxicol Ind Health. 1997 Jul-Aug;13(4):407-84
references.pmid: 9249929
references.citation: Clin Cancer Res. 2005 Dec 15;11(24 Pt 1):8782-8
references.pmid: 16361566
references.citation: J Thorac Oncol. 2010 Jul;5(7):1054-9
references.pmid: 20593550
references.citation: Leukemia. 2008 Jan;22(1):59-65
references.pmid: 17898789
references.citation: J Clin Oncol. 2008 Apr 20;26(12):2013-9
references.pmid: 18421054
references.citation: Cancer Chemother Pharmacol. 2010 Jul;66(2):245-54
references.pmid: 19841922
references.citation: Mol Cancer Ther. 2010 Oct;9(10):2737-51
references.pmid: 20924124
references.citation: Cancer Res. 1994 Mar 15;54(6):1517-28
references.pmid: 8137258